{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-039098","form_type":"8-K","ticker":null,"cik":"0001708331","company_name":"Virpax Pharmaceuticals, Inc.","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.683652+00:00","generated_at":"2026-06-03T00:40:47.491098+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Virpax CMO Jeffrey Gudin resigns as officer, continues as director; receives $81,900 severance","bullets":["Jeffrey Gudin resigned as Chief Medical Officer and EVP on May 2, 2024; no disagreement cited.","Separation agreement provides $81,900 paid semi-monthly over six months plus COBRA reimbursement.","Unvested options for 5,358 shares will continue to vest; total options for 20,616 shares.","Gudin remains a Class III Director of the company.","Agreement includes general release and non-disparagement clauses."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-039098","json":"https://secwatch.observer/filing/0001213900-24-039098.json","markdown":"https://secwatch.observer/filing/0001213900-24-039098.md","text":"https://secwatch.observer/filing/0001213900-24-039098.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708331/000121390024039098/0001213900-24-039098-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708331/000121390024039098/ea0205136-8k_virpax.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T00:40:47.491098+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dd0094fa56","claim":"Jeffrey Gudin resigned as Chief Medical Officer and Executive Vice President at Virpax Pharmaceuticals, Inc..","evidence_excerpt":"On May 2, 2024, Virpax Pharmaceuticals, Inc. (the “Company”) entered into a Separation Agreement and Release, dated May 2, 2024 (the “Separation Agreement”), with Jeffrey Gudin, MD pursuant to which Dr. Gudin resigned from his positions of Chief Medical Officer and Executive Vice President of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708331/000121390024039098/0001213900-24-039098-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Medical Officer and Executive Vice President"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}